Related Experiment Videos
Ewing's sarcoma and peripheral primitive neuroectodermal tumors after their genetic union
1Children's Cancer Research Institute (CCRI), St. Anna Kinderspital, Vienna, Austria.
Current Opinion in Oncology
|August 14, 1998
Summary
Ewing family of tumors are defined by EWS-ets gene rearrangements, which act as transforming transcription factors. Research is exploring genetic factors influencing treatment response and disease extension in these rare cancers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ewing family of tumors (EFT) are characterized by EWS-ets gene rearrangements.
- Recent molecular studies have identified unusual EFTs, expanding the classification.
- EWS-ets fusions are implicated as transforming transcription factors driving tumor development.
Purpose of the Study:
- To investigate potential molecular targets of EWS-ets fusions.
- To identify genetic factors correlating with clinical heterogeneity and treatment response in EFT.
- To understand the biological basis of variable disease extension in EFT.
Main Methods:
- Molecular techniques for visualizing EWS-ets gene rearrangements.
- Subtractive screening of transgenic fibroblasts to identify potential targets.
- Reverse transcriptase-polymerase chain reaction (RT-PCR) to assess metastasis at diagnosis.
Main Results:
- Identification of potential molecular targets for EWS-ets fusion proteins.
- Confirmation of EWS-ets fusion transcript structure's effect on localized disease.
- Frequent p16 tumor suppressor alterations observed in EFT.
- Metastasis at diagnosis identified as a major predictor of outcome via RT-PCR.
Conclusions:
- EWS-ets fusions are key oncogenic drivers in EFT.
- Genetic alterations, including p16, and metastatic status significantly influence EFT prognosis.
- Further research is needed to elucidate the diverse cellular contexts and biological mechanisms underlying EFT heterogeneity and disease extension.